Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839399 | 0.99 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CKDM4EKMT2A | |
| SCHEMBL6837805 | 0.98 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CKDM4EKMT2A | |
| SCHEMBL6837904 | 0.92 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CACHEMCHR1 | |
| SCHEMBL6838002 | 0.92 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CACHEMCHR1 | |
| SCHEMBL6838039 | 0.92 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CACHEMCHR1 | |
| SCHEMBL6837908 | 0.90 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CACHEMCHR1 | |
| SCHEMBL6837737 | 0.90 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CACHEMCHR1 | |
| SCHEMBL6837828 | 0.89 | RXFP1 (0.51) | ADRA2AADRA2BADRA2CKDM4EKMT2A | |
| SCHEMBL6837726 | 0.86 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CKDM4EKMT2A | |
| SCHEMBL6837962 | 0.85 | KMT2A (0.48) | ADRA2AADRA2BADRA2CKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | ADRA2A 1965/4885ADRA2B 1631/4885ADRA2C 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.